# Simcere Pharma

> Simcere Pharma is a VC fund in Nanjing backing Biotechnology and Health Care. See 10 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Nanjing, China
- Total investments: 10
- Last investment: Apr 2024
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/2094945
- Website: http://simcere.com

Simcere Pharma is a VC fund in Nanjing focused on Biotechnology and Health Care. Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a researchand development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million.

## Contacts

5 contacts available for Simcere Pharma. Shizune tracks 2 team members at Simcere Pharma. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/simcere-pharma?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 70% |
| Health Care | 5 | 50% |
| Biopharma | 4 | 40% |
| Pharmaceutical | 4 | 40% |
| Medical | 3 | 30% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 50% |
| Series B | 2 | 20% |
| Post-IPO Equity | 1 | 10% |
| Venture - Series Unknown | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 4 | 40% |
| United States | 3 | 30% |
| Taiwan | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jindong Zhou | Executive Vice President | 0 | — |
| Jinsheng Ren | Founder & Chairman | 0 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AnDiConBio | developer of respiratory anti-infection drugs, offering high-potential, low-risk products like new anti-influenza and oral anti-new coronavirus. | $27.6M | Series A | Apr 29, 2024 |  |
| Cornris Biotech | Cornris Biotech is a pharmaceutical company that specializes in research and development related to brain-transmitting drugs. |  | Series A | Dec 11, 2023 |  |
| Ningdan new drug | Ningdan New Drug is a developer of new drugs for central nervous system diseases. |  | Series A | Feb 08, 2023 |  |
| NeuroDawn Pharmaceutical | NeuroDawn Pharmaceutical develops new drugs that are designed to treat central nervous system diseases. | $14.7M | Series A | Feb 08, 2023 |  |
| Carmine Therapeutics | Carmine Therapeutics develops a novel type of gene therapy that utilizes extracellular vesicles produced in the laboratory. |  | Series A | Oct 13, 2022 |  |
| NeuroDawn Pharmaceutical | NeuroDawn Pharmaceutical develops new drugs that are designed to treat central nervous system diseases. | $1.5M | Series A | Aug 23, 2021 |  |
| Sidi Diagnostics | Sidi Diagnostics is a medical technology company that focuses on new molecular diagnostic technologies. | $40M | Venture - Series Unknown | Mar 01, 2020 |  |
| Amwise Diagnostic | Amwise Diagnostic is a leader in precision medicine technology for cancer. Our patented genetic analysis technologies assist doctors and patients in determining the most appropriate individualized treatment strategy that has optimal treatment effectiveness and minimal treatment-related adverse events. | $10M | Series B | Feb 26, 2020 |  |
| Veritas Genetics | Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer. The company's genetic technology can detect a wider range of variations in a gene than are typically found in next-generation sequencing and offers a screening test for hereditary breast and ovarian cancer risk, enablingclinical researchers and physicians in order to make informed decisions. | $30M | Series B | Oct 17, 2016 |  |
| NextCure | NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products. | $2M | Post-IPO Equity |  |  |

10 of 10 investments shown.

## Co-investors
- [Alphamab Oncology](https://shizune.co/investors/profile/alphamab-oncology) — VC Fund, 1 deal together
- China Merchants Health — VC Fund, 1 deal together
- [China Minsheng Investment Group](https://shizune.co/investors/profile/china-minsheng-investment-group) — VC Fund, 1 deal together
- [CICC Capital](https://shizune.co/investors/profile/cicc-capital) — VC Fund, 1 deal together
- [Cowin Capital](https://shizune.co/investors/profile/cowin-capital) — VC Fund, 1 deal together
- Drug Farm — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Simcere Pharma invest in?

Simcere Pharma invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Simcere Pharma?

Public channels for Simcere Pharma include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Simcere Pharma?

The team at Simcere Pharma includes Jindong Zhou (Executive Vice President) and Jinsheng Ren (Founder & Chairman). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co